(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization** International Bureau





(43) International Publication Date 11 November 2004 (11.11.2004)

PCT

(10) International Publication Number WO 2004/096853 A1

- (51) International Patent Classification7: C07K 14/595. 14/50, A61K 38/33, 38/18, C12N 15/09, A01K 67/027, A61P 3/10
- (21) International Application Number:

PCT/CA2004/000648

- (22) International Filing Date: 30 April 2004 (30.04.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/509,068

30 April 2003 (30.04.2003) US


- (71) Applicant (for all designated States except US): WARATAH PHARMACEUTICALS, INC. [CA/CA]; 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BRAND, Stephen J, [AU/US]; 161 Bedford Road, Lincoln, MA 01773 (US).

CRUZ, Antonio [CA/CA]; 89 Dunloe Road, Toronto, Ontario M5P 2T7 (CA).

- (74) Agents: KURDYDYK, Linda et al.; Suite 4700, Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMBINED USE OF KERATINOCYTE GROWTH FACTOR AGONISTS AND GASTRIN COMPOUNDS



KGF - 0.25 µg/Kg/day Gastrin - 1.5 µg/Kg/day

(57) Abstract: The invention relates generally to compositions, conjugates, and methods comprising a KGF agonist and a gastrin compound. The compositions can be used in the treatment and/or prevention of conditions for which either a KGF agonist or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, metabolic syndrome and related diseases and disorders, and obesity.



WO 2004/096853 A1



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.